HBV CARE 2026 will explore decentralised HBV care in an era of a changing treatment landscape.

Help Emily Martyn raise money to support Museum of Homelessness

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are among the world's leading infectious threats, together responsible for over a million deaths each year, but these infections remain neglected by...

Hasta un 40% de las organizaciones han reportado “altos impactos” en su trabajo, según encuestas hechas por la Coalición para la Eliminación Global de la Hepatitis y otros grupos que alertan sobre el ...

Introduction: Treatment of hepatitis B virus (HBV) primarily relies on nucleos(t)ide analogues to achieve viral suppression, with tenofovir or entecavir as first-line agents. Expanding treatment and i...

The availability of highly effective curative direct acting antiviral (DAA) therapy for hepatitis C virus (HCV) is a cornerstone of elimination strate…

Africa bears a disproportionate burden of hepatitis B virus (HBV) infection, with 68 million chronically infected individuals and 65% of global new in…

Introduction: Major cuts have been made to the global funding landscape since the beginning of 2025, including pausing or cancellation of existing grants, and cuts to specific organisations providing ...

This poster was presented at HBV meeting 2025

We are a team of clinicians and researchers based at the Francis Crick Institute in London, and working with international partners and collaborators to advance progress towards hepatitis B eliminatio...

Global health advocates and experts have warned that UK government cuts to overseas aid could threaten the country’s scientific leadership and collaborations.In March, the Labour government announced ...

Introduction: Major cuts have been made to the global funding landscape since the beginning of 2025, including pausing or cancellation of existing grants, and cuts to specific organisations providing ...

Leading infectious disease scientist warns of funding drying up and visa barriers for PhD students